Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
June 11 2010 - 8:10AM
Business Wire
Genta Incorporated (OTCBB: GETA.OB) announced that the Company
will host a conference call and live audio webcast of its 2010
Annual Meeting of Shareholders. The meeting will be held on
Tuesday, June 15, 2010 at 9:00 am ET at The Madison Hotel in
Morristown, NJ. Company management will present an overview of the
Company’s research programs, clinical and regulatory strategies,
and timelines.
Conference Call and Webcast Information:
Participants can access the live call by dialing (877) 634-8606
(U.S. and Canada) or (973) 200-3973 (International). The access
code for the live call is Genta Incorporated. The call will also be
webcast live at
http://www.genta.com/investorrelation/events.html.
For investors unable to participate in the live call, a replay
will be available approximately two hours after the completion of
the call, and will be archived for 30 days. Access numbers for this
replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291
(International); conference ID number is: 77021779.
Shareholders wishing to attend the meeting may call the hotel at
1-800-526-0729 for directions.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. Two
major programs anchor the Company’s research platform:
DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen
sodium) Injection is the Company's lead compound from its DNA/RNA
Medicines program. Genasense® is being developed as an agent that
may enhance the effectiveness of anticancer therapy. The Company is
currently collecting long-term followup data on durable response
and overall survival from the recently completed randomized Phase 3
study of Genasense® in patients with advanced melanoma (the AGENDA
trial). The Company is also developing tesetaxel, a novel, orally
absorbed, semi-synthetic taxane that is in the same class of drugs
as paclitaxel and docetaxel. Genta has initiated a broad clinical
program to evaluate the safety and efficacy of tesetaxel in
patients with solid tumors. In the U.S., Genta is exclusively
marketing Ganite® (gallium nitrate injection), which is indicated
for treatment of symptomatic patients with cancer-related
hypercalcemia that is resistant to hydration. The Company has
developed proprietary oral formulations of the active ingredient in
Ganite® that are being evaluated as potential treatments for
diseases associated with accelerated bone loss. Ganite® and
Genasense® are available on a “named-patient” basis in countries
outside the United States. For more information about Genta, please
visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. Such forward-looking
statements include those that express plan, anticipation, intent,
contingency, goals, targets, or future developments and/or
otherwise are not statements of historical fact. The words
“potentially”, “anticipate”, “could”, “calls for”, and similar
expressions also identify forward-looking statements. The Company
does not undertake to update any forward-looking statements.
Factors that could affect actual results include, without
limitation, risks associated with:
- the Company’s ability to obtain
necessary regulatory approval for its product candidates from
regulatory agencies, such as the U.S. Food and Drug Administration
and the European Medicines Agency;
- the safety and efficacy of the
Company’s products or product candidates;
- the commencement and completion
of any clinical trials;
- the Company’s assessment of its
clinical trials;
- the Company’s ability to
develop, manufacture, license, or sell its products or product
candidates;
- the Company’s ability to enter
into and successfully execute any license and collaborative
agreements;
- the adequacy of the Company’s
capital resources and cash flow projections, or the Company’s
ability to obtain sufficient financing to maintain the Company’s
planned operations;
- the adequacy of the Company’s
patents and proprietary rights;
- the impact of litigation that
has been brought against the Company; and
- the other risks described under
Certain Risks and Uncertainties Related to the Company’s Business,
as contained in the Company’s Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results
and developments to differ materially. For a discussion of those
risks and uncertainties, please see the Company's Annual Report on
Form 10-K for 2009 and its most recent quarterly report on Form
10-Q.